Comparison of Ticagrelor Versus Prasugrel to Prevent Periprocedural Myonecrosis in Acute Coronary Syndromes

American Journal of Cardiology

Volumn 116, Issue 3, 2015, Pages 339-343

  Bonello, Laurent ^a,b   Laine, Marc ^a   Cluzel, Marion ^a   Frere, Corinne ^b   Mancini, Julien ^c,d   Hasan, Aurasse ^g   Thuny, Franck ^a   Gaubert, Mélanie ^a   Guieu, Régis ^c,d   Dignat George, Françoise ^b,e   Michelet, Pierre ^c,d   Paganelli, Franck ^a   Kerbaul, François ^c,f  

^a HÔPITAL NORD   (France)

^b INSERM   (France)

^c AIX MARSEILLE UNIVERSITY   (France)

^d TIMONE HOSPITAL   (France)

^e HÔPITAL DE LA CONCEPTION   (France)

^f Service de Pneumologie Allergologje   (France)

^g Hopital de Martigues   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PRASUGREL; TICAGRELOR; TROPONIN I; ADENOSINE; PIPERAZINE DERIVATIVE; PURINERGIC P2Y RECEPTOR ANTAGONIST; THIOPHENE DERIVATIVE;

ACUTE CORONARY SYNDROME; ADULT; ANGIOGRAPHY; ARTICLE; CONTROLLED STUDY; CORONARY STENTING; FEMALE; FOLLOW UP; HEART MUSCLE NECROSIS; HOSPITAL ADMISSION; HUMAN; ISCHEMIA; LOADING DRUG DOSE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; NON ST ELEVATION ACUTE CORONARY SYNDROME; OPEN STUDY; PERCUTANEOUS CORONARY INTERVENTION; PERIPROCEDURAL MYONECROSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; ADOLESCENT; AGED; ANALOGS AND DERIVATIVES; COMPLICATION; DOSE RESPONSE; ELECTROCARDIOGRAPHY; MIDDLE AGED; MYOCARDIAL INFARCTION; TREATMENT OUTCOME; YOUNG ADULT;

ACUTE CORONARY SYNDROME; ADENOSINE; ADOLESCENT; ADULT; AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PIPERAZINES; PROSPECTIVE STUDIES; PURINERGIC P2Y RECEPTOR ANTAGONISTS; THIOPHENES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84937521309     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2015.04.050     Document Type: Article

References (21)

1. C.W. Hamm, J.P. Bassand, S. Agewall, J. Bax, E. Boersma, H. Bueno, P. Caso, D. Dudek, S. Gielen, K. Huber, M. Ohman, M.C. Petrie, F. Sonntag, M.S. Uva, R.F. Storey, W. Wijns, and D. Zahger ESC Committee for Practice Guidelines. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC) Eur Heart J 32 2011 2999 3054
2. S. Windecker, P. Kolh, F. Alfonso, J.P. Collet, J. Cremer, V. Falk, G. Filippatos, C. Hamm, S.J. Head, P. Jüni, A.P. Kappetein, A. Kastrati, J. Knuuti, U. Landmesser, G. Laufer, F.J. Neumann, D.J. Richter, P. Schauerte, M. Sousa Uva, G.G. Stefanini, D.P. Taggart, L. Torracca, M. Valgimigli, W. Wijns, and A. Witkowski 2014 ESC/EACTS guidelines on myocardial revascularization: the Task Force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic surgery (EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) Eur Heart J 35 2014 2541 2619
3. G. Montalescot, J.P. Collet, P. Ecollan, L. Bolognese, J. Ten Berg, D. Dudek, C. Hamm, P. Widimsky, J.F. Tanguay, P. Goldstein, E. Brown, D.L. Miller, L. LeNarz, E. Vicaut ACCOAST Investigators Pre-treatment with prasugrel in non-ST-segment elevation acute coronary syndromes N Engl J Med 369 2013 999 1010
4. G. Parodi, R. Valenti, B. Bellandi, A. Migliorini, R. Marcucci, V. Comito, N. Carrabba, A. Santini, G.F. Gensini, R. Abbate, and D. Antoniucci Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study J Am Coll Cardiol 61 2013 1601 1606
5. F. Mangiacapra, E. Barbato, G. Patti, L. Gatto, V. Vizzi, E. Ricottini, A. D'Ambrosio, W. Wijns, and G. Di Sciascio Point-of-care assessment of platelet reactivity after clopidogrel to predict myonecrosis in patients undergoing percutaneous coronary intervention JACC Cardiovasc Interv 3 2010 318 323
6. M. Valgimigli, G. Campo, N. de Cesare, E. Meliga, P. Vranckx, A. Furgieri, D.J. Angiolillo, M. Sabatè, M. Hamon, A. Repetto, S. Colangelo, S. Brugaletta, G. Parrinello, G. Percoco, R. Ferrari Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel (3T/2R) Investigators Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel study Circulation 119 2009 3215 3222
7. A. Prasad, M. Singh, A. Lerman, R.J. Lennon, D.R. Holmes Jr., and C.S. Rihal Isolated elevation in troponin T after percutaneous coronary intervention is associated with higher long-term mortality J Am Coll Cardiol 48 2006 1765 1770
8. T. Nageh, R.A. Sherwood, B.M. Harris, J.A. Byrne, and M.R. Thomas Cardiac troponin T and I and creatine kinase-MB as markers of myocardial injury and predictors of outcome following percutaneous coronary intervention Int J Cardiol 92 2003 285 293
9. D.N. Feldman, R.M. Minutello, G. Bergman, I. Moussa, and S.C. Wong Relation of troponin I levels following nonemergent percutaneous coronary intervention to short- and long-term outcomes Am J Cardiol 104 2009 1210 1215
10. P. Tricoci, S. Leonardi, J. White, H.D. White, P.W. Armstrong, G. Montalescot, R.P. Giugliano, C.M. Gibson, F. Van de Werf, R.M. Califf, R.A. Harrington, E. Braunwald, K.W. Mahaffey, and L.K. Newby Cardiac troponin after percutaneous coronary intervention and 1-year mortality in non-ST-segment elevation acute coronary syndrome using systematic evaluation of biomarker trends J Am Coll Cardiol 62 2013 242 251
11. K. Thygesen, J.S. Alpert, A.S. Jaffe, M.L. Simoons, B.R. Chaitman, and H.D. White Third universal definition of myocardial infarction J Am Coll Cardiol 60 2012 1581 1598
12. R. Mehran, S.V. Rao, D.L. Bhatt, C.M. Gibson, A. Caixeta, J. Eikelboom, S. Kaul, S.D. Wiviott, V. Menon, E. Nikolsky, V. Serebruany, M. Valgimigli, P. Vranckx, D. Taggart, J.F. Sabik, D.E. Cutlip, M.W. Krucoff, E.M. Ohman, P.G. Steg, and H. White Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium Circulation 123 2011 2736 2747
13. S.R. Mehta, S. Yusuf, R.J. Peters, M.E. Bertrand, B.S. Lewis, M.K. Natarajan, K. Malmberg, H. Rupprecht, F. Zhao, S. Chrolavicius, I. Copland, and K.A. Fox Effects of pre-treatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study Lancet 358 2001 527 533
14. S.R. Steinhubl, P.B. Berger, J.T. Mann III, E.T. Fry, A. DeLago, C. Wilmer, E.J. Topol CREDO Investigators Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. Clopidogrel for the reduction of events during observation JAMA 288 2002 2411 2420
15. D.L. Bhatt, G.W. Stone, K.W. Mahaffey, C.M. Gibson, P.G. Steg, C.W. Hamm, M.J. Price, S. Leonardi, D. Gallup, E. Bramucci, P.W. Radke, P. Widimský, F. Tousek, J. Tauth, D. Spriggs, B.T. McLaurin, D.J. Angiolillo, P. Généreux, T. Liu, J. Prats, M. Todd, S. Skerjanec, H.D. White, R.A. Harrington CHAMPION PHOENIX Investigators Effect of platelet inhibition with cangrelor during PCI on ischemic events N Engl J Med 368 2013 1303 1313
16. J.B. Selvanayagam, I. Porto, K. Channon, S.E. Petersen, J.M. Francis, S. Neubauer, and A.P. Banning Troponin elevation after percutaneous coronary intervention directly represents the extent of irreversible myocardial injury: insights from cardiovascular magnetic resonance imaging Circulation 111 2005 1027 1032
17. T. Cuisset, C. Frere, J. Quilici, P.E. Morange, J.P. Mouret, L. Bali, P.J. Moro, M. Lambert, M.C. Alessi, and J.L. Bonnet Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study JACC Cardiovasc Interv 1 2008 649 653
18. V. Pasceri, G. Patti, A. Nusca, C. Pristipino, G. Richichi, G. Di Sciascio ARMYDA Investigators Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study Circulation 110 2004 674 678
19. A. Bellemain-Appaix, S.A. O'Connor, J. Silvain, M. Cucherat, F. Beygui, O. Barthélémy, J.P. Collet, L. Jacq, F. Bernasconi, G. Montalescot ACTION Group Association of clopidogrel pre-treatment with mortality, cardiovascular events, and major bleeding among patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis JAMA 308 2012 2507 2516
20. M.T. Roe, P.W. Armstrong, K.A. Fox, H.D. White, D. Prabhakaran, S.G. Goodman, J.H. Cornel, D.L. Bhatt, P. Clemmensen, F. Martinez, D. Ardissino, J.C. Nicolau, W.E. Boden, P.A. Gurbel, W. Ruzyllo, A.J. Dalby, D.K. McGuire, J.L. Leiva-Pons, A. Parkhomenko, S. Gottlieb, G.O. Topacio, C. Hamm, G. Pavlides, A.R. Goudev, A. Oto, C.D. Tseng, B. Merkely, V. Gasparovic, R. Corbalan, M. Cintezə, R.C. McLendon, K.J. Winters, E.B. Brown, Y. Lokhnygina, P.E. Aylward, K. Huber, J.S. Hochman, E.M. Ohman TRILOGY ACS Investigators Prasugrel versus clopidogrel for acute coronary syndromes without revascularization N Engl J Med 367 2012 1297 1309
21. L. Bonello, M. Laine, N. Kipson, J. Mancini, O. Helal, J. Fromonot, V. Gariboldi, J. Condo, F. Thuny, C. Frere, L. Camoin-Jau, F. Paganelli, F. Dignat-George, and R. Guieu Ticagrelor increases adenosine plasma concentration in patients with an acute coronary syndrome J Am Coll Cardiol 63 2014 872 877